NCT01596140View on ClinicalTrials.gov

Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 18, 2012

Primary Completion Date

June 1, 2020

Study Completion Date

June 1, 2020

Conditions
Advanced CancerSolid Tumor
Interventions
DRUG

Vemurafenib

Starting dose 720 mg by mouth twice a day (3 tablets in the morning and 3 tablets in the evening) for 28-day study cycle.

DRUG

Everolimus

Starting dose 5.0 mg by mouth daily for 28-day study cycle.

DRUG

Temsirolimus

Starting dose 15 mg daily over 30-60 minutes on Days 1, 8, 15, and 22 of each 28-day cycle.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT01596140 - Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer | Biotech Hunter | Biotech Hunter